Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
A phase 1/2 trial of Fulvestrant in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.
Overview
Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients is a phase 1/2 interventional study registered as NCT07235176 by Qilu Pharmaceutical Co., Ltd., with 300 participants planned, started 2026-01-16 and due to reach its primary completion in 2028-11-02. Interventions recorded: QLS1304 tablet+Fulvestrant or QLC1401 and QLS1304 tablet+Fulvestrant，AI or QLC1401+CDK4/6i.
Similar pages
not linked directly; found by shared links- TrialGM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSNV4818 in Participants With Advanced Solid Tumors
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of MHB088C for Patients With Advanced Solid Malignant Tumors
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialCapivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.